Pharmacological characterization of isoproterenol-treated medaka fish

Pharmacological Research

Volumn 58, Issue 5-6, 2008, Pages 348-355

  Kawasaki, Takashi ^a   Saito, Kotaro ^a,b   Deguchi, Tomonori ^a   Fujimori, Kazuhiro ^a   Tadokoro, Mika ^a   Yuba, Shunsuke ^a   Ohgushi, Hajime ^a   Kawarabayasi, Yutaka ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Isoproterenol; Medaka fish

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTOXAMINE; COMPLEMENTARY DNA; ISOPRENALINE; MESSENGER RNA; METOPROLOL; PROPRANOLOL;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; DOSE RESPONSE; DRUG EFFECT; FISH; HEART HYPERTROPHY; HEART PROTECTION; HEART RATE; HEART SIZE; HEART VENTRICLE WALL; HISTOLOGY; LARVA; NONHUMAN; NUCLEOTIDE SEQUENCE; ORYZIAS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES COMPARISON; SWIMMING;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CARDIOMEGALY; HEART FUNCTION TESTS; HEART RATE; ISOPROTERENOL; LARVA; MOTOR ACTIVITY; MUSCLE FATIGUE; MYOCARDIUM; ORYZIAS; PROPRANOLOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 56649106452     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.011     Document Type: Article

References (26)

1. Beattie C.E., Carrel T.L., and McWhorter M.L. Fishing for a mechanism: using zebrafish to understand spinal muscular atrophy. J Child Neurol 22 (2007) 995-1003
2. Lemmens R., Van Hoecke A., Hersmus N., Geelen V., D'Hollander I., Thijs V., et al. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum Mol Genet 16 (2007) 2359-2365
3. Arnaout R., Ferrer T., Huisken J., Spitzer K., Stainier D.Y., Tristani-Firouzi M., et al. Zebrafish model for human long QT syndrome. Proc Natl Acad Sci U S A 104 (2007) 11316-11321
4. Bretaud S., Allen C., Ingham P.W., and Bandmann O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J Neurochem 100 (2007) 1626-1635
5. Sabaawy H.E., Azuma M., Embree L.J., Tsai H.J., Starost M.F., and Hickstein D.D. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 103 (2006) 15166-15171
6. Lam S.H., Wu Y.L., Vega V.B., Miller L.D., Spitsbergen J., Tong Y., et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 24 (2006) 73-75
7. Okubo K., Sakai F., Lau E.L., Yoshizaki G., Takeuchi Y., Naruse K., et al. Forebrain gonadotropin-releasing hormone neuronal development: insights from transgenic medaka and the relevance to X-linked Kallmann syndrome. Endocrinology 147 (2006) 1076-1084
8. Morgan H.E., and Baker K.M. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 83 1 (1991 Jan) 13-25
9. Schäfer M., Frischkopf K., Taimor G., Piper H.M., and Schlüter K.D. Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol 279 (2000) C495-503
10. Kitagawa Y., Yamashita D., Ito H., and Takaki M. Reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts. Am J Physiol Heart Circ Physiol 287 (2004) H277-285
11. Liao Y., Asakura M., Takashima S., Ogai A., Asano Y., Shintani Y., et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110 (2004) 692-699
12. Grimm D., Holmer S.R., Riegger G.A., and Kromer E.P. Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat. Cardiovasc Pathol 8 (1999) 315-323
13. Barone F.C., Nelson A.H., Ohlstein E.H., Willette R.N., Sealey J.E., Laragh J.H., et al. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 279 2 (1996 Nov) 948-955
14. Wakamatsu Y., Pristyazhnyuk S., Kinoshita M., Tanaka M., and Ozato K. The see-through medaka: a fish model that is transparent throughout life. Proc Natl Acad Sci USA 98 (2001) 10046-10050
15. Miller W., Rosenbloom K., Hardison R.C., Hou M., Taylor J., Raney B., et al. 28-way vertebrate alignment and conservation track in the UCSC Genome Browser. Genome Res 17 (2007) 1797-1808
16. Bartolome J., Huguenard J., and Slotkin T.A. Role of ornithine decarboxylase in cardiac growth and hypertrophy. Science 210 (1980) 793-794
17. Morimura N., Inoue T., Katayama K., and Aruga J. Comparative analysis of structure, expression and PSD95-binding capacity of Lrfn, a novel family of neuronal transmembrane proteins. Gene 380 (2006) 72-83
18. Wang X., Ren B., Liu S., Sentex E., Tappia P.S., and Dhalla N.S. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 94 (2003) 752-763
19. Perlini S., Ferrero I., Palladini G., Tozzi R., Gatti C., Vezzoli M., et al. Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure. Hypertension 48 (2006) 93-97
20. Strader C.D., Sigal I.S., Candelore M.R., Rands E., Hill W.S., and Dixon R.A. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem 263 (1988) 10267-10271
21. Lewell X.Q. A model of the adrenergic beta-2 receptor and binding sites for agonist and antagonist. Drug Des Discov 9 (1992) 29-48
22. Strader C.D., Sigal I.S., and Dixon R.A. Structural basis of beta-adrenergic receptor function. FASEB J 3 (1989) 1825-1832
23. Suryanarayana S., Daunt D.A., Von Zastrow M., and Kobilka B.K. A point mutation in the seventh hydrophobic domain of the alpha 2 adrenergic receptor increases its affinity for a family of beta receptor antagonists. J Biol Chem 266 (1991) 15488-15492
24. Cherksey B.D., Murphy R.B., and Zadunaisky J.A. Fluorescence studies of the beta-adrenergic receptor topology. Biochemistry 20 (1981) 4278-4283
25. Willette R.N., Aiyar N., Yue T.L., Mitchell M.P., Disa J., Storer B.L., et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 289 (1999) 48-53
26. Jakubetz J., Schmuck S., Poller U., Fuchs B., Gorf A., Radke J., et al. Cardiac effects of beta-adrenoceptor antagonists with intrinsic sympathomimetic activity in humans: beta1- and/or beta2-adrenoceptor mediated?. J Cardiovasc Pharmacol 33 (1999) 461-472